CONMED CORPORATION Deferred Revenue Recognized
CONMED CORPORATION (CNMD) reported Deferred Revenue Recognized of $9.40 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-07-29.
Financial Statements › Income Statement › Other Income
us-gaap:ContractWithCustomerLiabilityRevenueRecognized · last filed 2026-07-29
- CONMED CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2025-03-31 was $5.00M, a 4.17% increase year-over-year.
- CONMED CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2024-03-31 was $4.80M, a 14.29% increase year-over-year.
- CONMED CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2023-03-31 was $4.20M, a 7.69% increase year-over-year.
- CONMED CORPORATION contract with customer, liability, revenue recognized for the quarter ending 2022-03-31 was $3.90M, a 14.71% increase year-over-year.
- CONMED CORPORATION contract with customer, liability, revenue recognized for fiscal 2025 was $14.40M, a 3.60% increase from fiscal 2024.
- CONMED CORPORATION contract with customer, liability, revenue recognized for fiscal 2024 was $13.90M, a 11.20% increase from fiscal 2023.
- CONMED CORPORATION contract with customer, liability, revenue recognized for fiscal 2023 was $12.50M, a 8.70% increase from fiscal 2022.
- CONMED CORPORATION contract with customer, liability, revenue recognized for fiscal 2022 was $11.50M, a 11.65% increase from fiscal 2021.
| Period end | Contract with Customer, Liability, Revenue Recognized 3 month | Contract with Customer, Liability, Revenue Recognized 6 month | Contract with Customer, Liability, Revenue Recognized 9 month | Contract with Customer, Liability, Revenue Recognized 9 month as first filed | Contract with Customer, Liability, Revenue Recognized 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $9.40M 10-Q · filed 2026-07-29 | ||||
| 2025-12-31 | $14.40M 10-K · filed 2026-02-17 | ||||
| 2025-09-30 | $12.20M 10-Q · filed 2025-11-06 | ||||
| 2025-06-30 | $8.90M 10-Q · filed 2026-07-29 | ||||
| 2025-03-31 | $5.00M 10-Q · filed 2025-05-01 | ||||
| 2024-12-31 | $13.90M 10-K · filed 2026-02-17 | ||||
| 2024-09-30 | $11.60M 10-Q · filed 2025-11-06 | ||||
| 2024-06-30 | $8.50M 10-Q · filed 2025-07-31 | ||||
| 2024-03-31 | $4.80M 10-Q · filed 2025-05-01 | ||||
| 2023-12-31 | $12.50M 10-K · filed 2026-02-17 | ||||
| 2023-09-30 | $10.40M 10-Q · filed 2024-10-31 | ||||
| 2023-06-30 | $7.60M 10-Q · filed 2024-08-01 | ||||
| 2023-03-31 | $4.20M 10-Q · filed 2024-04-25 | ||||
| 2022-12-31 | $11.50M 10-K · filed 2025-02-18 | ||||
| 2022-09-30 | $9.50M 10-Q · filed 2023-10-26 | ||||
| 2022-06-30 | $7.00M 10-Q · filed 2023-07-27 | ||||
| 2022-03-31 | $3.90M 10-Q · filed 2023-04-27 | ||||
| 2021-12-31 | $10.30M 10-K · filed 2024-02-28 | ||||
| 2021-09-30 | $8.40M 10-Q · filed 2022-10-27 | ||||
| 2021-06-30 | $6.10M 10-Q · filed 2022-07-28 | ||||
| 2021-03-31 | $3.40M 10-Q · filed 2022-05-05 | ||||
| 2020-12-31 | $9.30M 10-K · filed 2023-02-21 | ||||
| 2020-09-30 | $7.60M 10-Q · filed 2021-10-28 | ||||
| 2020-06-30 | $5.50M 10-Q · filed 2021-07-29 | ||||
| 2020-03-31 | $3.00M 10-Q · filed 2021-04-29 | ||||
| 2019-12-31 | $6.80M 10-K · filed 2022-02-22 | ||||
| 2019-09-30 | $5.50M 10-Q · filed 2020-10-29 | ||||
| 2019-06-30 | $4.00M 10-Q · filed 2020-07-30 | ||||
| 2019-03-31 | $2.30M 10-Q · filed 2020-04-30 | ||||
| 2018-12-31 | $5.00M 10-K · filed 2021-02-22 | ||||
| 2018-09-30 | $4.10M 10-Q · filed 2019-10-31 | $6.60M 10-Q · filed 2018-11-02 | |||
| 2018-06-30 | $3.70M 10-Q · filed 2019-08-01 | ||||
| 2018-03-31 | $1.80M 10-Q · filed 2019-04-26 | ||||
| 2017-12-31 | $3.90M 10-K · filed 2020-02-24 | ||||
| 2017-09-30 | $4.70M 10-Q · filed 2018-11-02 | ||||
| 2017-06-30 | $3.00M 10-Q · filed 2018-08-02 | ||||
| 2017-03-31 | $1.50M 10-Q · filed 2018-04-26 | ||||
| 2016-12-31 | $3.50M 10-K · filed 2019-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Ceribell, Inc. (CBLL) | United States | $0.916B | -11.27 |
| BIOLIFE SOLUTIONS INC (BLFS) | United States | $1.887B | 23.80 |
| Axogen, Inc. (AXGN) | United States | $2.329B | -73.83 |
| CapsoVision, Inc (CV) | United States | $0.310B | -12.68 |
| Electromed, Inc. (ELMD) | United States | $0.233B | 31.13 |
| EDAP TMS SA (FOCL) | $0.171B | ||
| Stereotaxis, Inc. (STXS) | United States | $0.130B | -7.53 |
| Vivani Medical, Inc. (VANI) | United States | $0.111B | |
| electroCore, Inc. (ECOR) | United States | $0.102B | |
| Neuraxis, INC (NRXS) | United States | $0.097B |